ClinicalTrials.gg
RecruitingNCT06995261REWAGUpdated Jul 29, 2025

Follitropin Delta in Long GnRH-agonist Protocol

An observational study in Infertility (IVF Patients), Infertility and Infertility Drugs, sponsored by Prof. Dr. med. M.Sc. Georg Griesinger. Recruiting at 4 sites in Germany. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Prof. Dr. med. M.Sc. Georg Griesinger · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Infertility with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Infertility · Germany.

Planned enrollment
7th of 10
350 · median 1,023
Started
2025
the only one that year
Observational
10 of 28
4 open now
Registered
28th of 28
by date

Among the 28 studies in Infertility with a site in Germany, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2025, is one of 10 observational ones, and was the 28th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

4 of the 28 studies in Infertility with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 44 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Infertility with a site in Germany, or all of them as a file.
02

Study summary

The REWAG study ("Real-world Evaluation of Women undergoing Agonist protocol with Follitropin delta") is a non-interventional observational study conducted across several fertility centers in Germany. The goal of this study is to evaluate how well a personalized dosing regimen of a hormone called Follitropin delta works in women undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) using a long GnRH agonist protocol.

Follitropin delta is a recombinant follicle-stimulating hormone (rFSH) that allows for individualized dosing based on a woman's weight and a blood marker called anti-Müllerian hormone (AMH). This personalized approach may help to better balance the stimulation of the ovaries, aiming to reduce the risk of overstimulation (OHSS) while still achieving good treatment outcomes.

The study will include approximately 350 women who are undergoing routine IVF/ICSI treatment. No experimental drugs or procedures are involved. All treatment decisions remain the responsibility of the attending physicians and follow standard clinical practice. Data will be collected only from routine visits and medical documentation, with no additional interventions required for participation.

Researchers will analyze outcomes such as the number of eggs retrieved, pregnancy rates, treatment cancellations, and any side effects. The study will also look at whether certain patient characteristics can predict how well the treatment works or whether complications may arise.

Participation is voluntary. All personal data will be pseudonymized and handled according to strict data protection regulations (GDPR). Results will help to improve understanding of how personalized hormone dosing performs in real-life settings and may support more tailored and effective fertility treatments in the future.

03

Conditions studied

  • Infertility (IVF Patients)
  • Infertility
  • Infertility Drugs

Browse trials for

Keywords

  • follitropin delta
  • Rekovelle
  • Long GnRH-agonist protocol
  • individualized ovarian stimulation
  • Dosing algorithm
  • FSH
04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infertile women undergoing IVF oder ICSI. This study is intended to be conducted in non-vulnerable population. No vulnerable subjects will be enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 to ≤ 44 years at enrolment
  • Planned stimulation in a long luteal GnRH agonist protocol with daily s.c. GnRH-agonist
  • Planned use of Fd for ovarian stimulation as per SmPC
  • Serum AMH ≥0.3 ng/ml to ≤4.9 ng/ml measured within12 months prior to treatment
  • Most recent serum AMH value before start of stimulation not older than 12 months
  • Planned IVF or ICSI treatment in a first or second attempt with ejaculated or cryopreserved male germ cells, autologous or heterologous, with or without planned genetic testing of the oocytes or embryos
  • Planned triggering of final oocyte maturation with hCG
  • Willingness and consent to participate

Exclusion criteria

Exclusion Criteria:

  • Serum AMH value not determined in ELECSYS AMH Plus Immunoassay, ACCESS AMH Advanced (Beckham Coulter) or LUMIPULSE G AMH (Fujirebio)
  • Most recent serum AMH value before start of stimulation older than 12 months
  • Serum AMH within 12 months prior to treatment AMH ≤ 0.3 ng/ml or ≥4.9 ng/ml measured within 12 months prior to treatment
  • Pre-treatment with a combined oral "pill" consisting of ethinyl estradiol and a synthetic progestogen or a natural estradiol/progesterone
  • Anovulatory PCOS syndrome
  • Women with a for prescription of Fd treatment
  • Women undergoing ovarian stimulation for fertility preservation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • Follitropin Delta in Long GnRH Agonist Protocol

    This cohort includes women undergoing controlled ovarian stimulation for IVF or ICSI treatment using Follitropin delta administered in a long GnRH agonist protocol. The dosing is individualized based on AMH serum levels and body weight. Participants are treated according to routine clinical practice, and no study drug is provided. The study is non-interventional.

06

What researchers measure

Primary outcomes

  1. Ovarian Hyperstimulation Syndrome (OHSS)

    Ovarian Hyperstimulation Syndrome (OHSS) of any grade and any onset by Golan classification

    Time frame: From oocyte pick-up to gestational week 20

07

Study locations

4 of 4 sites recruiting
  • Department of Obstetrics, Gynecology and Reproductive Endocrinology (UniKiD), Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Recruiting
  • Center for Reproductive Medicine, IVF SAAR
    Saarbrücken, Saarland 66113, Germany
    Recruiting
  • Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein 24105, Germany
    Recruiting
  • Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus Lübeck
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
    • Georg Griesinger, MD · Contactgeorg.griesinger@uni-luebeck.de · + 49 451 505 778 212
    • Lilit Kamalyan, MD, PhD · Contactlilit.kamalyan@uksh.de · +49 451 505 778 212
    • Georg Griesinger · Principal investigator
    • Lilit Kamalyan · Sub investigator
    • Marion Depenbusch · Sub investigator
    • Askan Schultze-Mosgau · Sub investigator
    • Tanja Eggersmann · Sub investigator
08

References and documents

Publications

  • Lobo R, Soerdal T, Ekerhovd E, Cohlen B, Porcu E, Schenk M, Shufaro Y, Smeenk J, Suerdieck MB, Pinton P, Pinborg A; BEYOND Investigators. BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle. Hum Reprod. 2024 May 9;39(7):1481-94. doi: 10.1093/humrep/deae092. Online ahead of print. PubMed 38723189 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Of 209 non-industry observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 100. This study's planned 21 months is below that.

Counting every sponsor, half of 240 studies reached it within 39 months; a quarter within 16 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Dec 2027
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06995261
Lead sponsor
Prof. Dr. med. M.Sc. Georg Griesinger
Collaborators
University Hopsital Schleswig Holstein Campus Lübeck
Responsible party
Prof. Dr. med. M.Sc. Georg Griesinger (Professor of Gynecological Endocrinology and Reproductive Medicine, Director, IVF Center, University of Lübeck / UKSH, University of Luebeck) — Sponsor-investigator
First posted
May 29, 2025
Start date
Jul 9, 2025
Primary completion
Apr 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 29, 2025

Study contacts

Georg Griesinger, MD
Contact
georg.griesinger@uni-luebeck.de
+49 451 505 778 212
Lilit Kamalyan, MD, PhD
Contact
Lilit.Kamalyan@uksh.de
+49 451 505 778 212

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion